Dr Reddy's posts 28% revenue growth for fiscal 1st-qtr 2013

20 July 2012

India’s second largest drugmaker Dr Reddy’s Laboratories (NYSE: RDY) yesterday released unaudited consolidated financial results for the quarter ended June 30, 2012, showing that consolidated revenues reached 25.4 billion rupees ($460.5 million), reflecting year-on-year growth of 28%, driven by healthy growth in key markets of North America, Russia and other emerging markets in the global generics segment.

EBITDA of 5.07 billion rupees saw a rise of 16.8% and represented 20% of revenues. Profit after tax came in at 3.36 billion rupees, recording year-on-year growth of 28%, but missed analysts’ consensus expectations of 3.97 billion rupees. Diluted earnings per share were 19.7 rupees. During the quarter, the company launched 33 new generic products, filed 18 new product registrations and filed seven drug master files (DMFs) globally.

Global Generics revenues

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK